Rib-X Initiates Phase II Skin Infection Trial
Posted on: Wednesday, 16 July 2008, 12:01 CDT
Rib-X Pharmaceuticals has initiated a Phase II clinical trial for an intravenous form of antibiotic compound RX-3341 in the treatment of complicated skin and skin structure infections.
This Phase II double-blind study (study RX-3341-201) will evaluate the safety and efficacy of RX-3341 at two different doses administered intravenously to hospitalized complicated skin and skin structure infections (cSSSI) patients every 12 hours for five to 14 days, as compared to tigecycline (Tygacil).
The study's primary endpoint is the assessment of RX-3341 efficacy, safety and tolerability at the two different doses compared to that of tigecycline's standard dosing regimen. A secondary endpoint for the study is the assessment of clinical efficacy of RX-3341 compared to tigecycline in patients with cSSSIs caused by methicillin- resistant Staphylococcus aureus.
The safety and efficacy study will be conducted at 35 sites across the US. The company has also announced positive results of a two-part Phase I study with the same candidate.
The two-part Phase I study (RX-3341-103) compared the safety, tolerability and pharmacokinetics of two intravenous formulations of RX-3341. Part one of the study was designed to compare the safety and pharmacokinetics of the two IV formulations, with the purpose of optimizing the formulation of the IV dosage form.
Approximately 12 individuals received one dose of each of the formulations in a cross-over design. The two formulations were thus shown to be comparable in terms of exposure. The results showed that the chosen intravenous RX-3341 formulation was well tolerated using multiple doses for 14 days.
Source: Datamonitor
Related Articles
- Topical Cream Studied As Way To Treat Skin Cancer Without The Knife
- Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
- Lev Presents Results of Phase III Study Supporting Safety and Efficacy of Cinryze(TM) (C1 Inhibitor) As Prophylactic Therapy for HAE
- Gilead Study Confirms Atripla Efficacy
- Arpida Reports Positive Results of Second Pivotal Phase III Trial With Intravenous Iclaprim in cSSSI
- Aesthetic Medical Institute Introduces Skin Care Formulated to Aid and Enhance Professional Aesthetic Procedures
- Jazz Pharmaceuticals Announces Phase III Clinical Trial to Study the Safety and Efficacy of Xyrem(R) (Sodium Oxybate) in Patients With Fibromyalgia Syndrome
- Can-Fite to Initiate Clinical Studies to Test Efficacy of CF101 in Treating Dry Eyes Syndrome
- Altus Pharmaceuticals Announces Completion of Clinical Testing in the Phase I Study of ALTU-238 - a Long-Acting Crystalline Formulation of Human Growth Hormone
- New Study Reinforces Safety and Clinical Efficacy of ALK-Abello's Tablet Against Grass Pollen Allergy
 |
 |
User Comments (0)
RSS Feeds